Variable | Intervention (N = 108) | Control (N = 112) | p value |
---|---|---|---|
Age at Baseline |  |  | p = 0.33 |
 Median (Range) | 54 (26–86) | 56 (22–87) |  |
Time on Study (Days) |  |  | p = 0.64 |
 Median (Range) | 122 (49–482) | 113 (49–378) |  |
Gender |  |  | p = 0.89 |
 Male | 51 (47%) | 51 (46%) |  |
 Female | 57 (53%) | 61 (54%) |  |
Ethnicity/Race |  |  | p = 0.95 |
 Caucasian | 94 (87%) | 98 (87%) |  |
 Minority | 4 (4%) | 3 (3%) |  |
 Missing | 10 (9%) | 11 (10%) |  |
Working Status |  |  | p = 0.49 |
 Working | 72 (67%) | 79 (71%) |  |
 Not working | 29 (27%) | 23 (20%) |  |
 Missing | 7 (6%) | 10 (9%) |  |
Clinical Service |  |  | p = 0.83 |
 Medical Oncology | 95 (88%) | 100 (89%) |  |
 Radiation Oncology | 13 (12%) | 12 (11%) |  |
Cancer Diagnosisa |  |  | p = 0.83 |
 Breast | 34 (31%) | 42 (38%) |  |
 Head and Neck | 17 (16%) | 14 (12%) |  |
 Colorectal | 16 (15%) | 14 (12%) |  |
 Prostate | 12 (11%) | 10 (9%) |  |
 Esophageal | 7 (6%) | 3 (3%) |  |
 Testicular | 7 (6%) | 5 (4%) |  |
 Gastrointestinal Other | 4 (4%) | 2 (2%) |  |
 Other | 4 (4%) | 3 (3%) |  |
 Sarcoma | 3 (3%) | 0 |  |
 Bladder | 2 (2%) | 9 (8%) |  |
 Gastric | 2 (2%) | 5 (4%) |  |
 Pancreatic | 0 | 1 (1%) |  |
 Unknown Primary | 0 | 4 (4%) |  |
Stage |  |  | p = 0.29 |
 I | 14 (13%) | 19 (16%) |  |
 II | 30 (28%) | 29 (26%) |  |
 III | 30 (28%) | 22 (20%) |  |
 IV | 30 (28%) | 40 (36%) |  |
 Missing | 4 (4%) | 2 (2%) |  |
Chemotherapy Type |  |  | p = 0.98 |
 Taxane Only | 62 (58%) | 62 (55%) |  |
 Platinum Only | 39 (36%) | 42 (38%) |  |
 Platinum and Taxane | 7 (6%) | 8 (7%) |  |
Cumulative Dose Categoryb |  |  | p = 0.31 |
 Low Dosec | 25 (23%) | 26 (23%) |  |
 Moderate Dosed | 35 (32%) | 48 (43%) |  |
 High Dosee | 47 (44%) | 37 (33%) |  |
 Missing | 1 (1%) | 1 (%) |  |
Neurotoxic Chemotherapy Dose Reduction |  |  | p = 0.60 |
 None | 96 (89%) | 104 (93%) |  |
 Neuropathy-Related | 9 (8%) | 6 (5%) |  |
 Other Symptom-Relatedf | 3 (3%) | 2 (2%) |  |